BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 11758681)

  • 1. Renal pathological changes in Fabry disease.
    Sessa A; Meroni M; Battini G; Maglio A; Brambilla PL; Bertella M; Nebuloni M; Pallotti F; Giordano F; Bertagnolio B; Tosoni A
    J Inherit Metab Dis; 2001; 24 Suppl 2():66-70; discussion 65. PubMed ID: 11758681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of renal pathology in Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Nebuloni M; Tosoni A; Vago GL;
    Acta Paediatr Suppl; 2003 Dec; 92(443):6-8; discussion 5. PubMed ID: 14989458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis.
    Rozenfeld PA; de Los Angeles Bolla M; Quieto P; Pisani A; Feriozzi S; Neuman P; Bondar C
    Mol Genet Metab; 2020 Feb; 129(2):132-141. PubMed ID: 31718986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal ultrastructural findings in Anderson-Fabry disease.
    Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
    J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal involvement in Fabry disease.
    Abensur H; Reis MA
    J Bras Nefrol; 2016 Jun; 38(2):245-54. PubMed ID: 27438980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal disease in Fabry patients.
    Grünfeld JP; Lidove O; Joly D; Barbey F
    J Inherit Metab Dis; 2001; 24 Suppl 2():71-4; discussion 65. PubMed ID: 11758682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal involvement in paediatric Fabry disease.
    Sestito S; Falvo F; Sallemi A; Petrisano M; Scuderi MG; Tarsitano F; D'Angelo G; Betta P; Roppa K; Parisi F; Pensabene L; Fede C; Chimenz R; Concolino D
    J Biol Regul Homeost Agents; 2019; 33(5 Suppl. 1):59-63. Special Issue: Focus on Pediatric Nephrology. PubMed ID: 31630715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of renal pathology and dysfunction in children with Fabry disease.
    Ramaswami U; Najafian B; Schieppati A; Mauer M; Bichet DG
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):365-70. PubMed ID: 20056758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal transplantation in patients with Fabry disease.
    Sessa A; Meroni M; Battini G; Maglio A; Nebuloni M; Tosoni A; Panichi V; Bertagnolio B
    Nephron; 2002 Jun; 91(2):348-51. PubMed ID: 12053080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria and its consequences in renal disease.
    Schieppati A; Remuzzi G
    Acta Paediatr Suppl; 2003 Dec; 92(443):9-13; discussion 5. PubMed ID: 14989459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry Nephropathy: An Evidence-Based Narrative Review.
    Del Pino M; Andrés A; Bernabéu AÁ; de Juan-Rivera J; Fernández E; de Dios García Díaz J; Hernández D; Luño J; Fernández IM; Paniagua J; Posada de la Paz M; Rodríguez-Pérez JC; Santamaría R; Torra R; Ambros JT; Vidau P; Torregrosa JV
    Kidney Blood Press Res; 2018; 43(2):406-421. PubMed ID: 29558749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal complications of Fabry disease in children.
    Najafian B; Mauer M; Hopkin RJ; Svarstad E
    Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
    Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
    Lee MH; Choi EN; Jeon YJ; Jung SC
    Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.